Navigation Links
Actavis Full Year 2012 Net Revenue Increases 29% to $5.91 Billion
Date:2/19/2013

of Actavis Group. 

Actavis Specialty Brands R&D investment in the fourth quarter increased $23.8 million due to higher in-licensing costs and increased costs related to our biosimilar product development.  Actavis Specialty Brands selling and marketing expenses decreased by $1.2 million to $45.3 million in the fourth quarter, primarily due to lower promotional spending in the U.S., partially offset by higher commercial spending in Canada.

For the full year 2012, Actavis Specialty Brands segment net revenue increased 9 percent to $482.4 million, due to increased sales of Generess Fe® which was launched in the second quarter of 2011 and sales growth for key promoted products including  Rapaflo® and Crinone® and the addition of  Kadian®.

Actavis Specialty Brands segment adjusted gross margin for the full year 2012 was 76.1 percent, compared to 78.7 percent in 2011 as a result of product mix. Anda Distribution Segment InformationThree Months EndedTwelve Months EndedDecember 31, December 31,(Unaudited; $ in millions)2012201120122011Net revenue

$
203.9$
251.4$
986.4$
776.2Operating expenses:Cost of sales

168.1214.6846.6652.7Selling and marketing

21.320.889.877.2Segment contribution

$
4.5$
.0$
50.0$
46.3Segment margin

7.1%6.4%5.1%6.0%Gross profit

$
35.8$
36.8$
39.8$
23.5Gross margin

17.6%14.6%14.2%15.9%Anda Distribution segment net revenue for the fourth quarter 2012 decreased 19 percent to $203.9 million compared to $251.4 million in the fourth quarter 2011 due to lower chain sales offset by new product launches. Anda Distribution segment revenue consists only of sales of third-party products and excludes sales of Actavis' brand and generic products.

Anda Distribution segment gross margin increased 300 basis points to 17.6 percent in the fourth quarter 2012, prim
'/>"/>

SOURCE Actavis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Watson to Acquire Actavis Group for EUR4.25 Billion
2. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
3. Actavis Launches Generic Equivalent of Adalat® CC 90mg (Nifedipine Extended-Release Tablets, USP)
4. Watson and Actavis Receive FTC Second Request
5. Watson Announces New Name -- Actavis -- for Global Operations
6. Watson Pharmaceuticals, Inc. is Now Actavis, Inc.
7. Actavis, Inc. to Host Fourth Quarter 2012 Earnings Conference Call and Webcast
8. Actavis, Inc. to Present at the RBC Capital Markets Healthcare Conference
9. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
10. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
11. Aethlon Medical Note: Fiscal Year Revenue Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  ... Award" from the Journal of Drugs in Dermatology ... Clinical Conference (ODAC). The event is January 17-20, 2014, at the ... . The ODAC is a ...
(Date:1/15/2014)... Jan. 15, 2014  Manufacturers, suppliers and distributors of ... to protect their most important business assets, intellectual ... ) Because of the highly-competitive nature ... one of the most litigious industry sectors of ...
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment of ... Executive Officer.  Mark was promoted from his current role of ... four facilities in Massachusetts , ... Medical in 2012 with 20+ years of broad-based operations, sales, ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... Shire plc (LSE: SHP, Nasdaq: SHPGY ), ... its long-term extension to its open label Phase I/II study ... therapy for patients with type 1 Gaucher disease.  The data ... Gaucher Disease (EWGGD) in Cologne, Germany , and add ...
... July 1 Sagent Pharmaceuticals, Inc., a privately ... Food and Drug Administration (FDA) has approved the Company,s ... a vital anticoagulant, preventing the formation of clots and ... in surgical and dialysis settings.  According to IMS, 2009 ...
Cached Medicine Technology:Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months 2Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months 3Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months 4Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months 5Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months 6FDA Approves Sagent Pharmaceuticals' Heparin Sodium Injection, USP 2FDA Approves Sagent Pharmaceuticals' Heparin Sodium Injection, USP 3FDA Approves Sagent Pharmaceuticals' Heparin Sodium Injection, USP 4
(Date:4/18/2014)... This news release is available in French . ... breakthrough could revolutionize surgical practice and regenerative medicine. A ... Molle et Chimie (CNRS/ESPCI Paris Tech) and Didier Letourneur ... and Paris 13), has just demonstrated that the principle ... used in vivo to repair soft-tissue organs and tissues. ...
(Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... Il. (April 17, 2014) Doctors who treat ... called lymphangioleiomyomatosis (LAM) can face an agonizing treatment ... of the disease and help relieve shortness of ... transplants, and sirolimus can cause potentially fatal complications ... pulmonologist Dr. Daniel Dilling, medical director of Loyola ...
(Date:4/17/2014)... from Boston University School of Medicine (BUSM) have ... consumption in an experimental model. The findings, reported ... Alcohol Abuse , may lead to more effective ... is one of the leading causes of illness ... negative economic impact by limiting the productivity of ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2
... can do a lot to keep kids safe, experts say, , ... to be), youngsters are probably going to be spending less ... doing cannonballs. , It,s all fun and games -- until someone ... warn child safety experts. , Though many injuries amount to little ...
... Invited to Attend , , NEW ORLEANS, June 6 ... New Orleans for the 2009 Catholic Health Assembly, "In Our ... , The assembly, hosted by the Catholic Health Association of ... Catholic health care leaders from across the nation. They come ...
... ... Low Vision Conditions , ... Beach, CA (PRWEB) June 6, 2009 -- Enhanced Vision , America,s leading manufacturer of ... VISION 5K Run & Walk in Boston, MA this Saturday, June 7th. The unique event ...
... , - These acquisitions reinforce Genomma Lab,s presence in the cosmetics ... lotions and perfumes segments , , - Genomma Lab continues ... place in June 2008 , , ... C.V. (BMV: LAB) ("Genomma Lab" or "the Company"), one of ...
... study found diabetes drug didn,t increase chances of heart disease, ... drug Avandia significantly raises the risk of both heart failure ... for either cardiovascular disease or death, new research has found. ... risk of death, said the authors of the much-anticipated RECORD ...
... June 5 NxStage Medical, Inc. (Nasdaq: ... today announced it has completed the closing of its ... alliance partner, Asahi Kasei Kuraray Medical. The Company used ... its entire debt obligation, including prepayment and other transaction ...
Cached Medicine News:Health News:Summer Fun Need Not Be Hazardous 2Health News:2009 Catholic Health Assembly to Focus on Hope in a Time of Hardship and Adapting for the Future in a Time of Health Reform 2Health News:2009 Catholic Health Assembly to Focus on Hope in a Time of Hardship and Adapting for the Future in a Time of Health Reform 3Health News:Enhanced Vision Supports America's Leading Event for Blind and Visually Impaired 2Health News:Enhanced Vision Supports America's Leading Event for Blind and Visually Impaired 3Health News:Genomma Lab Internacional Acquires Brands Flor de Naranja Sanborns(MR), Teatrical and Henna Egipcia From Grupo Sanborns 2Health News:Avandia Raises Risk of Heart Failure, Fractures 2Health News:Avandia Raises Risk of Heart Failure, Fractures 3Health News:Avandia Raises Risk of Heart Failure, Fractures 4Health News:NxStage Announces Closing of $40 Million Debt Financing with Asahi Kasei Kuraray Medical 2
... a sterile, nonpyrogenic, viscoelastic preparation of ... weight fraction of sodium hyaluronate., ,Healon ... dissolved in physiological sodium chloride phosphate ... weight polymer is made up of ...
... System is designed to give two viscoelastic ... be used differently and sequentially to perform ... choice of the viscoelastic is based upon ... each to facilitate performance of the surgical ...
... During fiscal year 2004, Biomet ... Navigation System to the global market, ... procedures. The Acumen technology was developed ... private company based in Hollywood, Florida. ...
... in awhile, a product comes along that ... in its category. The new StealthStation TREON ... a product. Built on the phenomenal success ... surgical navigation system in the worldthe new ...
Medicine Products: